pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
STAT·May 4·1 min read
save

Experts question the validity of blue zones concept amid new genetic study

May 4, 2026·read at STAT ↗Neutral

The opinion piece by medical journalist Shelley Wood and cardiologist Eric Topol examines growing doubts about the “blue zones” idea, which originally described a handful of Sardinian villages noted for many centenarians.

The authors cite French geneticist Jean-Francois Deleuze’s AGENOMICS study, launched in 2022 to compare genetic patterns of French centenarians with those from classic blue zones, and note that Deleuze now questions the premise after recent findings.

They argue that the concept has been stretched by wellness trends and commercial interests, and that the scientific basis for attributing longevity to lifestyle alone is increasingly uncertain.

source

This writeup was produced by pharmadog from original reporting by STAT.

Original headline: “Opinion: Are blue zones real? Answering that question is harder than ever”

read at STAT ↗
2,778 words · retrieved May 4
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
LEADING2
drugs
Obesity
topics
Diagnostics CompanyObesityOphthalmology

related stories

  • Apr 30Remembering J. Craig Venter: a relentless scientist who changed biotech — and was all too easily misunderstoodSTAT
  • 5d agoAstraZeneca inks $1.5B insitro deal for AI-enabled target discovery of liver, heart disease drugsFierce Biotech
  • Oct 2This week in charts: Kodiak’s big comeback and Hengrui’s dealmakingBioPharma Dive
  • Sep 22Siemens Healthineers and Novo team up on fatty liver disease awareness, testingFierce Biotech
  • Sep 15Businesses can now apply for NIH fundingSTAT